Status:

COMPLETED

A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients.

Lead Sponsor:

Hoffmann-La Roche

Conditions:

Anemia

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This study will assess the efficacy and safety of intravenous (iv) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving ...

Eligibility Criteria

Inclusion

  • adult patients \>=18 years of age;
  • chronic renal anemia;
  • on dialysis therapy for at least 12 weeks before screening;
  • receiving darbepoetin alfa iv for at least 8 weeks before screening.

Exclusion

  • women who are pregnant, breastfeeding or using unreliable birth control methods;
  • administration of another investigational drug within 4 weeks before screening, or during the study period.

Key Trial Info

Start Date :

March 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2005

Estimated Enrollment :

313 Patients enrolled

Trial Details

Trial ID

NCT00077766

Start Date

March 1 2004

End Date

August 1 2005

Last Update

October 26 2016

Active Locations (48)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 12 (48 locations)

1

Blacktown, Australia, NSW 2148

2

Brisbane, Australia, 4102

3

Clayton, Australia, 3168

4

Gosford, Australia, 2250